[Show abstract] [Hide abstract]
ABSTRACT: We evaluated whether the ERCC1 polymorphisms had an effect on survival in epithelial ovarian cancer (EOC) patients with platinum-based chemotherapy.
Clinical data of 209 EOC patients between 2002 and 2008 were reviewed. The genotypes of 19007T/C and 8092C/A polymorphisms were assessed in all patients using PCR-RFLP.
The 19007T/C polymorphism was significantly associated with response to treatment. Compared with the patients carrying C/C genotype, the patients with the T/T genotype have a significantly decreased response to platinum-based chemotherapy (odds ratio: 32.26; 95% CI: 3.66-250.00). Cox's multivariate analysis suggested that EOC patients with the T/T genotype had an increased risk of disease progression (hazard ratio: 3.34; 95% CI: 1.77-6.29) and death (hazard ratio: 2.87; 95% CI: 1.38-5.96) compared with those carrying the C/C genotype.
The 19007T/C polymorphism may be a useful prognostic marker in patients with EOC treated with platinum-based chemotherapy in Chinese women.
Pharmacogenomics 03/2012; 13(4):419-27. DOI:10.2217/pgs.11.181 · 3.22 Impact Factor